Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Yes, press releases routinely make Alzheimer’s discoveries sound more certain than they really are. Research examining hundreds of university press releases has found that roughly one-third contain exaggerated causal claims, and about 40% contain exaggerated advice about what the findings mean for patients and families. The issue isn’t always intentional deception—it’s a combination of how science is communicated, the pressure researchers face to appear confident about their work, and the reality that journalists often rely heavily on press releases when reporting breakthroughs. But the cumulative effect is real: families hoping for answers about treatment or prevention may encounter headlines that sound far more conclusive than the underlying science actually supports.
This problem became impossible to ignore when a major Alzheimer’s theory came under fire. In 2023, Science magazine reported allegations that images in a widely-cited 2006 Nature study by neuroscientist Sylvain Lesné had been doctored. That study proposed that a particular protein assembly, called protofibrils, might be a key target for Alzheimer’s treatment. The theory attracted billions in research funding and shaped the direction of drug development for years—all based partly on research that may have been fabricated. It’s an extreme example, but it highlights why the difference between what a press release claims and what the actual evidence shows matters deeply to people making healthcare decisions.
Table of Contents
- How Press Releases Exaggerate What Alzheimer’s Research Actually Shows
- The Alzheimer’s Problem Is More Acute Than Other Fields
- Why Journalists Rely on Press Releases (And Why That’s a Problem)
- A Cautionary Tale: When Exaggerated Findings Shape Years of Research
- The System That Creates Exaggeration
- Signs of Progress in More Honest Science Communication
- What Families and Patients Should Know Going Forward
- Conclusion
How Press Releases Exaggerate What Alzheimer’s Research Actually Shows
When researchers publish a study, universities and research institutions typically issue press releases designed to highlight the significance of the work. These summaries are meant to help journalists and the public understand the findings. But studies that examined hundreds of these releases found consistent patterns of overstatement. One analysis of major UK university press releases discovered that 40% contained exaggerated advice, 33% contained exaggerated causal claims (saying something “causes” a problem when the study only found a correlation), and 36% overstated how well findings from animal research might apply to humans. The mechanics of this exaggeration are often subtle rather than dramatic. A study might show that a particular molecule reduced plaques in mice brains under laboratory conditions. The press release might describe this as a “promising new approach to clearing Alzheimer’s plaques,” which sounds like progress toward human treatment.
But there’s a vast gap between a laboratory result in animals and an actual therapy that helps people. That gap rarely gets the same attention as the hopeful finding itself. When journalists pick up the press release and write their headline, they’re working from material that has already nudged the science slightly toward certainty. The problem extends to how press releases frame causation. In Alzheimer’s research, many studies are observational—they show that people with a certain gene variant, diet pattern, or lifestyle factor have different brain health outcomes. A press release might say the research “shows that sleep deprivation causes cognitive decline,” when the actual study showed an association in one group of people, without proving cause and effect. This distinction matters because it shapes what families actually do in response.
The Alzheimer’s Problem Is More Acute Than Other Fields
Alzheimer’s disease research faces a particular communication challenge because so many findings come from animal studies or early laboratory work. Researchers work with mice engineered to develop amyloid plaques, cell cultures, or brain tissue samples—not with living human brains. These studies are essential for early science, but they are fundamentally limited. A molecule that clears plaques from a mouse brain might not work the same way in human neurodegeneration, where the disease involves numerous interconnected problems across decades of life. Research examining headlines in Alzheimer’s news coverage found that journalists and press releases frequently omit whether findings are based on animal research rather than human studies.
Readers see “Scientists Find New Way to Clear Brain Plaques” and may not realize the work was done in mice or in laboratory dishes. For a disease where millions of people and families are desperate for effective treatments, this gap between what we know from animal models and what might eventually help humans gets obscured by the time information reaches the public. The stakes of this communication gap are higher in Alzheimer’s because there is currently no cure, and available treatments offer limited benefit. When a press release makes a mouse study sound like a potential breakthrough, it can raise false hope. Families might also make decisions based on incomplete information—deciding whether to enroll in a clinical trial, pursue certain diets or supplements, or adjust care plans based on what they believe is proven science, when the evidence is much more preliminary than headlines suggest.
Why Journalists Rely on Press Releases (And Why That’s a Problem)
Press releases serve a critical function in science communication, but they also create a bottleneck for accuracy. Most journalists covering science don’t have time to read the full academic paper, understand the methodology, check the sample size, or assess whether the findings have been independently replicated. They rely on press releases as a starting point—a summary from the institution itself, which presumably understands the work best. When that summary exaggerates causation or overstates implications, journalists often don’t catch it because they’re working under deadline pressure and limited resources. This dynamic has been documented directly.
Research showed that inaccuracies in news stories about health research frequently originate in the press releases themselves. When scientists or press officers present findings in ways that increase perceived importance and don’t mention study limitations, those oversimplifications tend to flow straight into public coverage. A journalist might add a quote or context, but the foundation—the framing that something is more certain or more immediately relevant than it really is—comes from the institutional press release. For Alzheimer’s research, this means that when a university announces a finding, it often reaches families through a chain of communication where each step is one step further from the original research. The press release simplifies for accessibility, the news headline simplifies further for impact, social media shares simplify even more, and by the time a family member reads a Facebook post about the research, the uncertainty and caveats have largely disappeared. The original scientific discovery—often important but preliminary—has become “a new Alzheimer’s treatment is on the way.”.
A Cautionary Tale: When Exaggerated Findings Shape Years of Research
The Sylvain Lesné case illustrates what happens when exaggerated claims about a study gain massive influence before anyone seriously questions the underlying data. In 2006, Lesné’s team published a Nature paper suggesting that a specific protein assembly called protofibrils was central to Alzheimer’s pathology and could be a target for treatment. The paper received significant attention, and the theory built from it attracted enormous research investment and shaped the direction of Alzheimer’s drug development for more than a decade. In 2023, Science magazine published an investigation revealing allegations that images in Lesné’s 2006 paper had been altered or manipulated. The investigation found “clear evidence of image manipulation” in figures that were central to the paper’s conclusions.
This discovery threw the entire theoretical foundation into serious question. If the key evidence was fabricated or significantly altered, then the theory that launched thousands of subsequent studies and billions in research funding was built on a corrupted foundation. Researchers who had spent years developing drugs based on the protofibril hypothesis found themselves questioning whether they were pursuing the right target. What’s striking is how long it took for serious scrutiny of the images to occur, and how the press releases and media coverage around Lesné’s work never mentioned these concerns. The institutional communication around the research presented it as solid science, which meant journalists reported it as such, and the field built upon it. This is an extreme case, but it demonstrates why the certainty conveyed in press releases—even when the actual research includes significant caveats—matters for how science advances and what gets funded.
The System That Creates Exaggeration
Scientists and universities face genuine pressures that incentivize hyped findings over cautious ones. Researchers seeking grants must compete for limited funding, and funders are more likely to support work that sounds important and promising than work described with appropriate uncertainty. Universities depend on research reputation and media attention to attract donors and top students. Individual scientists navigate career advancement systems where publications in high-impact journals and media attention matter for getting hired, promoted, and funded. Productivity metrics have increasingly taken on a greater role in scientific advancement. The “publish or perish” system encourages scientists to present their work in the most compelling light possible.
A press release that says “we found an interesting preliminary result that needs further study” is less likely to generate media coverage and external funding than one that says “we discovered a potential new treatment approach.” These aren’t conscious decisions to deceive—they’re rational responses to institutional incentives that often reward certainty over caution. This systemic pressure is complicated to resolve because it involves the entire structure of how science is funded, how scientists advance their careers, and how institutions measure success. Simply telling researchers and communications officers to be more careful hasn’t fully solved the problem, though progress is possible. When academic attention focuses on exaggeration in press releases, institutions do respond. One study found that after public criticism of exaggerated causal claims in press releases, the rate of causal overstatement in press releases dropped from 28% in 2014 to 13% in 2015. The improvement shows that awareness and accountability can shift behavior, at least temporarily.
Signs of Progress in More Honest Science Communication
The improvement in causal overstatement rates between 2014 and 2015—dropping from 28% to 13%—shows that when the issue gets public attention, some institutions and researchers do adjust their communication. This isn’t a complete solution, but it demonstrates that change is possible without requiring dramatic overhauls of the scientific system. Some universities and research centers have begun training communications staff specifically on how to present research accurately without exaggerating implications or certainty.
Professional organizations have also started emphasizing the importance of accurate press releases. Guidelines now encourage researchers and communications professionals to mention study limitations, describe whether work was done in animals or humans, specify the size and nature of the study population, and avoid language suggesting certainty when evidence is preliminary. These are relatively straightforward improvements that don’t require changing how science is conducted—just how it’s described to the public.
What Families and Patients Should Know Going Forward
As Alzheimer’s research continues advancing, the communication challenges aren’t going away. The field will keep publishing mouse studies, early trials, and observational research that forms the foundation for eventual human treatments. Press releases will continue playing a role in how that research reaches the public.
But awareness of these patterns can help families approach Alzheimer’s news with appropriate skepticism. When you encounter a headline about a new Alzheimer’s breakthrough, it’s worth asking: Is this research in humans or animals? How preliminary is the stage of research? What does the actual scientific team say about when this might become available to patients? The fact that a major Alzheimer’s theory was potentially built on fabricated research underscores that scientific uncertainty is not a failure of the process—it’s built into legitimate science. Research advances through many steps, with many findings proving less significant or applicable than initial presentations suggest. That’s not a problem to fix by hyping preliminary results; it’s a feature that requires honest communication about what we actually know at each stage.
Conclusion
Press releases do make Alzheimer’s discoveries sound more certain than the evidence typically supports, and this happens through a combination of institutional incentives, journalism limitations, and genuine scientific uncertainty. The research is clear: roughly one-third of university press releases about health research contain exaggerated causal claims, and about 40% contain exaggerated advice. For Alzheimer’s disease specifically, where families are desperate for hope and treatments remain limited, this gap between actual evidence and how findings are presented has real consequences.
The good news is that this problem is not inevitable or unchangeable. When institutions face public attention and criticism for exaggerated claims, rates of overstatement do decline. Families, patients, and caregivers can protect themselves by learning to read Alzheimer’s research news critically—asking whether studies involved humans or animals, what the actual study size was, and how preliminary the findings remain. Supporting more honest science communication means encouraging your institutions, media sources, and researchers to describe what we actually know with appropriate uncertainty, rather than claiming certainty where science doesn’t yet exist.
You Might Also Like
- How Families Can Avoid Misreading Alzheimer’s Test Headlines
- Can Personalized Alzheimer’s Plans Become Standard?
- Can False Positives Harm Alzheimer’s Patients?
Related reading
- why Dementia Diagnosis Still Needs Clinical Evaluation
- can Biomarkers Replace a Neurologist
- how Doctors Combine Symptoms, Tests, and Imaging
- why Memory Testing Still Matters in the Biomarker Era
- could New Tests Miss Non-Alzheimer’s Dementia
For more on this topic, see NIH MedlinePlus — cognitive testing.
